Positive outcome of first-line therapy for a SMARCA4-deficient thoracic sarcomatoid tumor

SMARCA4-deficient thoracic sarcomatoid tumor is a rare malignancy indicating some characteristics of a smoking-related disease. The purpose of this report is to describe a case of aggressive thoracic tumor with loss of immunochemical SMARCA4 expression and detail the results of our treatment regimen...

Full description

Saved in:
Bibliographic Details
Published in:International cancer conference journal 2021-04, Vol.10 (2), p.112-115
Main Authors: Tanaka, Shigeru, Hayashi, Shuhei, Isobe, Yoshitaka, Maruyama, Eiichi, Ozawa, Hiroaki, Okuno, Motoyasu, Kondo, Masaru
Format: Article
Language:English
Subjects:
Cancer therapies
Carboplatin
Case Report
Chemotherapy
Consent
Emphysema
Genomes
Immunotherapy
Lung cancer
Malignancy
Medical imaging
Medicine
Medicine & Public Health
Morphology
Mutation
Oncology
Ovaries
Pembrolizumab
Pleural effusion
Sarcoma
Surgical Oncology
Thorax
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SMARCA4-deficient thoracic sarcomatoid tumor is a rare malignancy indicating some characteristics of a smoking-related disease. The purpose of this report is to describe a case of aggressive thoracic tumor with loss of immunochemical SMARCA4 expression and detail the results of our treatment regimen. The patient was a 58-year-old male and clinicopathologically diagnosed with a SMARCA4-deficient thoracic sarcomatoid tumor. Pembrolizumab plus carboplatin and pemetrexed resulted in significant response. This combination therapy showed potential for first-line systemic treatment of SMARCA4-deficient thoracic sarcomatoid tumors.
ISSN:2192-3183
2192-3183
DOI:10.1007/s13691-021-00472-4